{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:10:45Z","timestamp":1792797045594,"version":"4.5.0"},"reference-count":242,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011652","name":"Indian Institute of Science Education and Research Mohali","doi-asserted-by":"publisher","award":["CSIR-09\/1178"],"award-info":[{"award-number":["CSIR-09\/1178"]}],"id":[{"id":"10.13039\/501100011652","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011652","name":"Indian Institute of Science Education and Research Mohali","doi-asserted-by":"publisher","award":["18009"],"award-info":[{"award-number":["18009"]}],"id":[{"id":"10.13039\/501100011652","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.bbcan.2025.189318","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T11:11:31Z","timestamp":1744369891000},"page":"189318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comprehensive insights of etiological drivers of hepatocellular carcinoma: Fostering targeted nano delivery to anti-cancer regimes"],"prefix":"10.1016","volume":"1880","author":[{"given":"Dipanjan","family":"Ghosh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aharna","family":"Guin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aryan","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amlan","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santanu","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2025.189318_bb0005","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictios to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbcan.2025.189318_bb0010","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bbcan.2025.189318_bb0015","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3350\/cmh.2023.0070","article-title":"The latest global burden of liver cancer: a past and present threat","volume":"29","author":"Oh","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.bbcan.2025.189318_bb0020","doi-asserted-by":"crossref","first-page":"S361","DOI":"10.21037\/jgo.2020.02.08","article-title":"Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management","volume":"12","author":"Samant","year":"2021","journal-title":"J. Gastroint. Oncol."},{"key":"10.1016\/j.bbcan.2025.189318_bb0025","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bbcan.2025.189318_bb0030","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","article-title":"Epidemiology of viral hepatitis and hepatocellular carcinoma","volume":"142","author":"El-Serag","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbcan.2025.189318_bb0035","first-page":"1054","article-title":"Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases\u2014meta-analytic assessment","volume":"8","author":"Tarao","year":"2019"},{"key":"10.1016\/j.bbcan.2025.189318_bb0040","series-title":"Molecular Pathogenesis of Hepatocellular Carcinoma and Impact of Therapeutic Advances [Version 1; Peer Review: 4 Approved], 5","author":"Dhanasekaran","year":"2016"},{"key":"10.1016\/j.bbcan.2025.189318_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4254\/wjh.v11.i1.1","article-title":"Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review","volume":"11","author":"Desai","year":"2019","journal-title":"World journal of hepatology"},{"key":"10.1016\/j.bbcan.2025.189318_bb0050","first-page":"1","article-title":"Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis","volume":"16","author":"Ghouri","year":"2017","journal-title":"J. Carcinogen."},{"key":"10.1016\/j.bbcan.2025.189318_bb0055","series-title":"Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease","volume":"10","author":"Suresh","year":"2020"},{"key":"10.1016\/j.bbcan.2025.189318_bb0060","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2045-3701-1-5","article-title":"Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine?","volume":"1","author":"Kumar","year":"2011","journal-title":"Cell Biosci."},{"key":"10.1016\/j.bbcan.2025.189318_bb0065","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12951-022-01309-9","article-title":"Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances","volume":"20","author":"Mahmoud","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.bbcan.2025.189318_bb0070","article-title":"Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis","volume":"9","author":"Liu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2025.189318_bb0075","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"European Association for the Study of the, research treatment of Cancer, EASL\u2013EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"56","author":"L.E.O.f.","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbcan.2025.189318_bb0080","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.3748\/wjg.v20.i15.4141","article-title":"Staging systems of hepatocellular carcinoma: a review of literature","volume":"20","author":"Maida","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bbcan.2025.189318_bb0085","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.2217\/nnm.13.118","article-title":"Current trends in the use of liposomes for tumor targeting","volume":"8","author":"Deshpande","year":"2013","journal-title":"Nanomedicine (London)"},{"key":"10.1016\/j.bbcan.2025.189318_bb0090","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12943-024-02101-z","article-title":"Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma","volume":"23","author":"Chan","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2025.189318_bb0095","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2147\/IJN.S149196","article-title":"Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles","volume":"13","author":"Chen","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.bbcan.2025.189318_bb0100","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/wnan.1390","article-title":"Nanoparticle formulations of cisplatin for cancer therapy","volume":"8","author":"Duan","year":"2016","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.bbcan.2025.189318_bb0105","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1091\/mbc.e14-04-0916","article-title":"How Taxol\/paclitaxel kills cancer cells","volume":"25","author":"Weaver","year":"2014","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.bbcan.2025.189318_bb0110","first-page":"198","article-title":"Side effects related to systemic cancer treatment: are we changing the promethean experience with molecularly targeted therapies?","volume":"15","author":"De Angelis","year":"2008","journal-title":"Curr. Oncol. (Toronto, Ont.)"},{"key":"10.1016\/j.bbcan.2025.189318_bb0115","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.addr.2018.07.007","article-title":"Tumor targeting via EPR: strategies to enhance patient responses","volume":"130","author":"Golombek","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbcan.2025.189318_bb0120","doi-asserted-by":"crossref","first-page":"1296091","DOI":"10.3389\/fonc.2024.1296091","article-title":"Lipid-based nanoparticles as drug delivery carriers for cancer therapy","volume":"14","author":"Waheed","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2025.189318_bb0125","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1039\/C6CS00636A","article-title":"Cellular uptake of nanoparticles: journey inside the cell","volume":"46","author":"Behzadi","year":"2017","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.bbcan.2025.189318_bb0130","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1111\/jcmm.13110","article-title":"Overviews on the cellular uptake mechanism of polysaccharide colloidal nanoparticles","volume":"21","author":"Salatin","year":"2017","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.bbcan.2025.189318_bb0135","article-title":"Cellular uptake and retention of nanoparticles: insights on particle properties and interaction with cellular components","volume":"25","author":"Augustine","year":"2020","journal-title":"Mater. Today Commun."},{"key":"10.1016\/j.bbcan.2025.189318_bb0140","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1080\/10717544.2022.2089296","article-title":"Functional ligands for improving anticancer drug therapy: current status and applications to drug delivery systems","volume":"29","author":"Bajracharya","year":"2022","journal-title":"Drug Deliv."},{"key":"10.1016\/j.bbcan.2025.189318_bb0145","series-title":"Artificial Cells","first-page":"42","article-title":"2 - polymeric hydrophilic polymers in targeted drug delivery","author":"Poon","year":"2007"},{"key":"10.1016\/j.bbcan.2025.189318_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.601710","article-title":"Etiology of hepatocellular carcinoma: special focus on fatty liver disease","volume":"10","author":"Suresh","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2025.189318_bb0155","first-page":"232","article-title":"Hepatitis C and alcohol","volume":"27","author":"Schiff","year":"2003","journal-title":"Alcohol Res. Health"},{"key":"10.1016\/j.bbcan.2025.189318_bb0160","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.14309\/ajg.0000000000000340","article-title":"Alcohol consumption and risk of liver cirrhosis: a systematic review and Meta-analysis","volume":"114","author":"Roerecke","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.bbcan.2025.189318_bb0165","first-page":"37","article-title":"Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors, nature reviews","volume":"20","author":"Huang","year":"2023","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbcan.2025.189318_bb0170","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.3892\/ol.2013.1169","article-title":"Aflatoxin B1-induced hepatocellular carcinoma in developing countries: geographical distribution, mechanism of action and prevention","volume":"5","author":"Hamid","year":"2013","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bbcan.2025.189318_bb0175","doi-asserted-by":"crossref","first-page":"1215428","DOI":"10.3389\/fmicb.2023.1215428","article-title":"Disease burden contributed by dietary exposure to aflatoxins in a mountainous city in Southwest China","volume":"14","author":"Qin","year":"2023","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.bbcan.2025.189318_bb0180","doi-asserted-by":"crossref","first-page":"5905357","DOI":"10.1155\/2021\/5905357","article-title":"Tobacco smoking and liver cancer risk: potential avenues for carcinogenesis","volume":"2021","author":"Jain","year":"2021","journal-title":"J. Oncol."},{"key":"10.1016\/j.bbcan.2025.189318_bb0185","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jhep.2022.01.016","article-title":"Cigarette smoking and liver diseases","volume":"77","author":"Marti-Aguado","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbcan.2025.189318_bb0190","first-page":"617","article-title":"Smoking and liver disease","volume":"16","author":"Rutledge","year":"2020","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbcan.2025.189318_bb0195","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jhep.2009.09.012","article-title":"Vinyl chloride and the liver","volume":"51","author":"Sherman","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbcan.2025.189318_bb0200","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00292-007-0954-2","article-title":"Hereditary hemochromatosis, alpha-1-antitrypsin deficiency and Wilson\u2019s disease. Pathogenesis, clinical findings and pathways to diagnosis","volume":"29","author":"Zhou","year":"2008","journal-title":"Pathologe"},{"key":"10.1016\/j.bbcan.2025.189318_bb0205","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10123202","article-title":"Pathogenesis and current treatment strategies of hepatocellular carcinoma","volume":"10","author":"T\u00fcmen","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.bbcan.2025.189318_bb0210","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2174\/1568026620666200106145340","article-title":"Telomere-related markers for Cancer","volume":"20","author":"Yuan","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bbcan.2025.189318_bb0215","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2202157119","article-title":"Oncogenic \u03b2-catenin stimulation of AKT2-CAD-mediated pyrimidine synthesis is targetable vulnerability in liver cancer","volume":"119","author":"Liu","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2025.189318_bb0220","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ygeno.2013.04.001","article-title":"Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections","volume":"102","author":"Tornesello","year":"2013","journal-title":"Genomics"},{"key":"10.1016\/j.bbcan.2025.189318_bb0225","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/ng.2256","article-title":"Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma","volume":"44","author":"Guichard","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2025.189318_bb0230","first-page":"17","article-title":"Targeting the Cholecystokinin Receptor: A Novel Approach for Treatment and Prevention of Hepatocellular Cancer, Cancer prevention research (Philadelphia Pa.)","volume":"14","author":"Gay","year":"2021"},{"key":"10.1016\/j.bbcan.2025.189318_bb0235","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.31557\/APJCP.2020.21.4.1031","article-title":"XRCC1 gene polymorphism increases the risk of hepatocellular carcinoma in Egyptian population","volume":"21","author":"Naguib","year":"2020","journal-title":"Asian Pacific J. Cancer Prevent."},{"key":"10.1016\/j.bbcan.2025.189318_bb0240","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-230X-5-17","article-title":"Hepatocellular carcinoma and the penetrance of HFE C282Y mutations: a cross sectional study","volume":"5","author":"Willis","year":"2005","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.bbcan.2025.189318_bb0245","doi-asserted-by":"crossref","first-page":"5563","DOI":"10.1158\/0008-5472.CAN-18-3750","article-title":"SNAI1 promotes the Cholangiocellular phenotype, but not epithelial-mesenchymal transition, in a murine hepatocellular carcinoma model","volume":"79","author":"Xu","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189318_bb0250","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41418-018-0211-7","article-title":"Suppressor of hepatocellular carcinoma RASSF1A activates autophagy initiation and maturation","volume":"26","author":"Li","year":"2019","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bbcan.2025.189318_bb0255","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/s41419-022-05411-6","article-title":"MYC and MET cooperatively drive hepatocellular carcinoma with distinct molecular traits and vulnerabilities","volume":"13","author":"Sequera","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2025.189318_bb0260","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/s41419-021-04166-w","article-title":"TCF4 enhances hepatic metastasis of colorectal cancer by regulating tumor-associated macrophage via CCL2\/CCR2 signaling","volume":"12","author":"Tu","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2025.189318_bb0265","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/15353702211049149","article-title":"CCNB1 promotes the development of hepatocellular carcinoma by mediating DNA replication in the cell cycle","volume":"vol. 247","author":"Rong","year":"2022","journal-title":"Exp. Biol. Med. (Maywood, N.J.)"},{"key":"10.1016\/j.bbcan.2025.189318_bb0270","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s12276-020-00551-1","article-title":"Hepatocyte nuclear factor 4\u03b1 and cancer-related cell signaling pathways: a promising insight into cancer treatment","volume":"53","author":"Lv","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bbcan.2025.189318_bb0275","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/2211-5463.12043","article-title":"SNAI1 promotes the development of HCC through the enhancement of proliferation and inhibition of apoptosis","volume":"6","author":"Qi","year":"2016","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.bbcan.2025.189318_bb0280","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fcell.2020.00055","article-title":"The function of the HGF\/c-met Axis in hepatocellular carcinoma","volume":"8","author":"Wang","year":"2020","journal-title":"Front. Cell Develop. Biol."},{"key":"10.1016\/j.bbcan.2025.189318_bb0285","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.760971","article-title":"IL-6\/STAT3 is a promising therapeutic target for hepatocellular carcinoma","volume":"11","author":"Xu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2025.189318_bb0290","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1053\/hupa.2002.128061","article-title":"Smad4 overexpression in hepatocellular carcinoma is strongly associated with transforming growth factor beta II receptor immunolabeling","volume":"33","author":"Torbenson","year":"2002","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.bbcan.2025.189318_bb0295","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/ijc.25127","article-title":"TGF-beta inactivation and TGF-alpha overexpression cooperate in an in vivo mouse model to induce hepatocellular carcinoma that recapitulates molecular features of human liver cancer","volume":"127","author":"Baek","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbcan.2025.189318_bb0300","doi-asserted-by":"crossref","first-page":"8978930","DOI":"10.1155\/2020\/8978930","article-title":"The DNMT1\/miR-34a\/FOXM1 Axis contributes to Stemness of liver Cancer cells","volume":"2020","author":"Cao","year":"2020","journal-title":"J. Oncol."},{"key":"10.1016\/j.bbcan.2025.189318_bb0305","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12951-021-00777-9","article-title":"Protein liposomes-mediated targeted acetylcholinesterase gene delivery for effective liver cancer therapy","volume":"19","author":"Wang","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.bbcan.2025.189318_bb0310","article-title":"High hepatic leukemia factor expression indicates a favorable survival in glioma patients","volume":"100","author":"Liu","year":"2021","journal-title":"Medicine"},{"key":"10.1016\/j.bbcan.2025.189318_bb0315","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1038\/onc.2014.425","article-title":"SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma","volume":"34","author":"Hernanda","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2025.189318_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcp.2023.101944","article-title":"USP5: comprehensive insights into structure, function, biological and disease-related implications, and emerging therapeutic opportunities","volume":"73","author":"Gao","year":"2024","journal-title":"Mol. Cell. Probes"},{"key":"10.1016\/j.bbcan.2025.189318_bb0325","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/1471-2105-15-198","article-title":"CIRCUS: a package for Circos display of structural genome variations from paired-end and mate-pair sequencing data","volume":"15","author":"Naquin","year":"2014","journal-title":"BMC Bioinforma."},{"key":"10.1016\/j.bbcan.2025.189318_bb0330","series-title":"Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma","volume":"12","author":"Zheng","year":"2022"},{"key":"10.1016\/j.bbcan.2025.189318_bb0335","volume":"10","author":"Fern\u00e1ndez","year":"2020","journal-title":"Alterat. Lipid Metab. Cancer Implications Prognosis Treatment."},{"key":"10.1016\/j.bbcan.2025.189318_bb0340","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cmet.2019.11.010","article-title":"Greasing the wheels of the Cancer machine: the role of lipid metabolism in Cancer","volume":"31","author":"Snaebjornsson","year":"2020","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbcan.2025.189318_bb0345","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061419","article-title":"Lipid metabolism in development and progression of hepatocellular carcinoma","volume":"12","author":"Sangineto","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2025.189318_bb0350","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/mco2.27","article-title":"Lipid metabolism in cancer progression and therapeutic strategies","volume":"2","author":"Fu","year":"2021","journal-title":"MedComm"},{"key":"10.1016\/j.bbcan.2025.189318_bb0355","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41389-022-00420-8","article-title":"Lipids in cancer: a global view of the contribution of lipid pathways to metastatic formation and treatment resistance","volume":"11","author":"Vasseur","year":"2022","journal-title":"Oncogenesis"},{"key":"10.1016\/j.bbcan.2025.189318_bb0360","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1053\/j.gastro.2010.12.006","article-title":"Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma","volume":"140","author":"Calvisi","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbcan.2025.189318_bb0365","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1111\/j.1742-4658.2012.08644.x","article-title":"Lipid metabolism in cancer","volume":"279","author":"Santos","year":"2012","journal-title":"FEBS J."},{"key":"10.1016\/j.bbcan.2025.189318_bb0370","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cmet.2015.05.014","article-title":"Acetyl coenzyme a: a central metabolite and second messenger","volume":"21","author":"Pietrocola","year":"2015","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbcan.2025.189318_bb0375","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ceb.2015.02.003","article-title":"Acetyl-CoA and the regulation of metabolism: mechanisms and consequences","volume":"33","author":"Shi","year":"2015","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.bbcan.2025.189318_bb0380","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.canlet.2018.08.006","article-title":"Fatty acid oxidation: an emerging facet of metabolic transformation in cancer","volume":"435","author":"Ma","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2025.189318_bb0385","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/hep.28415","article-title":"Acetyl-coenzyme A carboxylase alpha promotion of glucose-mediated fatty acid synthesis enhances survival of hepatocellular carcinoma in mice and patients","volume":"63","author":"Wang","year":"2016","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"Suppl","key":"10.1016\/j.bbcan.2025.189318_bb0390","doi-asserted-by":"crossref","first-page":"S138","DOI":"10.1194\/jlr.R800079-JLR200","article-title":"Fatty acid metabolism: target for metabolic syndrome","volume":"50","author":"Wakil","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbcan.2025.189318_bb0395","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3892\/ijo.2017.3867","article-title":"Inhibition of FASN suppresses migration, invasion and growth in hepatoma carcinoma cells by deregulating the HIF-1\u03b1\/IGFBP1 pathway","volume":"50","author":"Gong","year":"2017","journal-title":"Int J Oncol"},{"key":"10.1016\/j.bbcan.2025.189318_bb0400","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.3892\/or.2014.3484","article-title":"Expression and roles of fatty acid synthase in hepatocellular carcinoma","volume":"32","author":"Hao","year":"2014","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bbcan.2025.189318_bb0405","first-page":"479","article-title":"The role of stearoyl-coenzyme a desaturase 1 in clear cell renal cell carcinoma, tumour biology: the journal of the international society for","volume":"37","author":"Wang","year":"2016","journal-title":"Oncodev. Biol. Med."},{"key":"10.1016\/j.bbcan.2025.189318_bb0410","doi-asserted-by":"crossref","first-page":"52203","DOI":"10.1074\/jbc.M305760200","article-title":"Overexpression of diacylglycerol acyltransferase-1 reduces phospholipid synthesis, proliferation, and invasiveness in simian virus 40-transformed human lung fibroblasts","volume":"278","author":"Bagnato","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2025.189318_bb0415","article-title":"Cancer cells stemness: a doorstep to targeted therapy","volume":"1866","author":"Prasad","year":"2020","journal-title":"Biochimica et Biophysica Acta (BBA) - Mol. Basis Dis."},{"key":"10.1016\/j.bbcan.2025.189318_bb0420","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41392-020-0110-5","article-title":"Targeting cancer stem cell pathways for cancer therapy","volume":"5","author":"Yang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2025.189318_bb0425","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/nm.4409","article-title":"Cancer stem cells revisited","volume":"23","author":"Batlle","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2025.189318_bb0430","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13046-018-0784-5","article-title":"Emerging role of lipid metabolism alterations in Cancer stem cells","volume":"37","author":"Yi","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189318_bb0435","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.stem.2017.12.017","article-title":"Phospholipid remodeling and cholesterol availability regulate intestinal Stemness and tumorigenesis","volume":"22","author":"Wang","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.bbcan.2025.189318_bb0440","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1158\/0008-5472.CAN-17-0114","article-title":"MYC-regulated mevalonate metabolism maintains brain tumor-initiating cells","volume":"77","author":"Wang","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189318_bb0445","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1101\/gad.324301.119","article-title":"Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer","volume":"33","author":"Gimple","year":"2019","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbcan.2025.189318_bb0450","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003769","article-title":"C-Myc is required for maintenance of glioma Cancer stem cells","volume":"3","author":"Wang","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2025.189318_bb0455","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12943-017-0646-3","article-title":"Emerging roles of lipid metabolism in cancer metastasis","volume":"16","author":"Luo","year":"2017","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2025.189318_bb0460","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/jb\/mvr088","article-title":"Secreted phospholipase A2 revisited","volume":"150","author":"Murakami","year":"2011","journal-title":"J. Biochem."},{"key":"10.1016\/j.bbcan.2025.189318_bb0465","doi-asserted-by":"crossref","first-page":"22557","DOI":"10.1074\/jbc.R114.574152","article-title":"Phospholipase D in cell signaling: from a myriad of cell functions to cancer growth and metastasis","volume":"289","author":"Gomez-Cambronero","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2025.189318_bb0470","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1124\/mol.107.040105","article-title":"Effects of active and inactive phospholipase D2 on signal transduction, adhesion, migration, invasion, and metastasis in EL4 lymphoma cells","volume":"74","author":"Knoepp","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbcan.2025.189318_bb0475","doi-asserted-by":"crossref","first-page":"5551","DOI":"10.1038\/onc.2013.207","article-title":"Phospholipase D (PLD) drives cell invasion, tumor growth and metastasis in a human breast cancer xenograph model","volume":"32","author":"Henkels","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2025.189318_bb0480","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1388-1981(00)00044-5","article-title":"Fatty acid import into mitochondria","volume":"1486","author":"Kerner","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbcan.2025.189318_bb0485","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.mam.2004.06.002","article-title":"Carnitine acyltransferases and their influence on CoA pools in health and disease","volume":"25","author":"Ramsay","year":"2004","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.bbcan.2025.189318_bb0490","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.bulcan.2017.03.013","article-title":"Cabozantinib: mechanism of action, efficacy and indications","volume":"104","author":"Cochin","year":"2017","journal-title":"Bull. Cancer"},{"key":"10.1016\/j.bbcan.2025.189318_bb0495","series-title":"FDA approves cabozantinib for hepatocellular carcinoma","author":"US-FDA","year":"2019"},{"key":"10.1016\/j.bbcan.2025.189318_bb0500","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.tips.2022.12.007","article-title":"Futibatinib (Lytgobi) for cholangiocarcinoma","volume":"44","author":"Roskoski","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bbcan.2025.189318_bb0505","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","article-title":"Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF\/FGFR aberrations: a Phase I dose-expansion study","volume":"12","author":"Meric-Bernstam","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2025.189318_bb0510","doi-asserted-by":"crossref","first-page":"40","DOI":"10.4103\/1319-3767.37808","article-title":"Sorafenib in the treatment of advanced hepatocellular carcinoma","volume":"14","author":"Ben Mousa","year":"2008","journal-title":"Saudi J. Gastroenterol."},{"key":"10.1016\/j.bbcan.2025.189318_bb0515","first-page":"187","article-title":"Lenvantinib: a tyrosine kinase inhibitor of VEGFR 1-3, FGFR 1-4, PDGFR\u03b1, KIT and RET, recent results in cancer research","volume":"211","author":"Zsch\u00e4bitz","year":"2018","journal-title":"Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer"},{"key":"10.1016\/j.bbcan.2025.189318_bb0520","series-title":"FDA approves lenvatinib for unresectable hepatocellular carcinoma","author":"US-FDA","year":"2018"},{"key":"10.1016\/j.bbcan.2025.189318_bb0525","first-page":"838","article-title":"FDA approval summary: Pemigatinib for previously treated, Unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or other rearrangement, clinical cancer research: an official journal of the American association for","volume":"29","author":"Patel","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189318_bb0530","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s42004-022-00718-z","article-title":"Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants","volume":"5","author":"Lin","year":"2022","journal-title":"Commun. Chem."},{"key":"10.1016\/j.bbcan.2025.189318_bb0535","article-title":"INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models","volume":"15","author":"Liu","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2025.189318_bb0540","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1186\/s12967-023-04450-7","article-title":"Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor microRNAs","volume":"21","author":"Pace","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bbcan.2025.189318_bb0545","series-title":"Regorafenib Becomes First FDA-Approved Drug for Liver Cancer in Nearly a Decade","author":"N.C.I. (NIH)","year":"2017"},{"key":"10.1016\/j.bbcan.2025.189318_bb0550","first-page":"122","article-title":"The role of Regorafenib in hepatocellular carcinoma","volume":"13","author":"Frenette","year":"2017","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbcan.2025.189318_bb0555","series-title":"Advances in Cancer Research","first-page":"257","article-title":"Chapter six - systemic therapy of liver cancer","author":"Demir","year":"2021"},{"key":"10.1016\/j.bbcan.2025.189318_bb0560","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40265-021-01567-1","article-title":"Infigratinib: first approval","volume":"81","author":"Kang","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.bbcan.2025.189318_bb0565","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1007\/s00432-021-03703-6","article-title":"Upregulation of the ErbB family by EZH2 in hepatocellular carcinoma confers resistance to FGFR inhibitor","volume":"147","author":"Prawira","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2025.189318_bb0570","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4103\/1735-5362.235156","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages","volume":"13","author":"Ghasemiyeh","year":"2018","journal-title":"Res. Pharmaceut. Sci."},{"key":"10.1016\/j.bbcan.2025.189318_bb0575","first-page":"641","article-title":"Biocompatible and biodegradable nanoparticles for enhancement of anti-cancer activities of phytochemicals","volume":"13","author":"Li","year":"2015","journal-title":"Chin. J. Nat. Med."},{"key":"10.1016\/j.bbcan.2025.189318_bb0580","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1021\/acsmaterialsau.3c00032","article-title":"Lipid-based nanoparticles for drug\/gene delivery: an overview of the production techniques and difficulties encountered in their industrial development","volume":"3","author":"Mehta","year":"2023","journal-title":"ACS Materials Au"},{"key":"10.1016\/j.bbcan.2025.189318_bb0585","article-title":"An insight on lipid nanoparticles for therapeutic proteins delivery","volume":"77","author":"Viegas","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.bbcan.2025.189318_bb0590","doi-asserted-by":"crossref","first-page":"2100109","DOI":"10.1002\/anbr.202100109","article-title":"Lipid nanoparticles for drug delivery","volume":"2","author":"Xu","year":"2022","journal-title":"Adv. NanoBiomed Res."},{"key":"10.1016\/j.bbcan.2025.189318_bb0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.ntm.2024.100054","article-title":"Anticancer lipid-based drug delivery systems: basic knowledge and recent applications","volume":"3","author":"Shehata","year":"2024","journal-title":"Nano TransMed"},{"key":"10.1016\/j.bbcan.2025.189318_bb0600","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2012.06.002","article-title":"Improvement of drug safety by the use of lipid-based nanocarriers","volume":"163","author":"Lim","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbcan.2025.189318_bb0605","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.addr.2007.04.012","article-title":"Nanostructured lipid carriers (NLC) in cosmetic dermal products","volume":"59","author":"M\u00fcller","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbcan.2025.189318_bb0610","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejps.2017.11.023","article-title":"Formulations based on solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for cutaneous use: a review","volume":"112","author":"Garc\u00eas","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bbcan.2025.189318_bb0615","first-page":"3009","article-title":"Lipid-based nanocarriers for the oral administration of biopharmaceutics, nanomedicine: nanotechnology, biology","volume":"11","author":"Karamanidou","year":"2016","journal-title":"Fortschr. Med."},{"key":"10.1016\/j.bbcan.2025.189318_bb0620","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2020.111046","article-title":"Influence of formulation variables on miconazole nitrate\u2013loaded lipid based nanocarrier for topical delivery","volume":"193","author":"Al-Maghrabi","year":"2020","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.bbcan.2025.189318_bb0625","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12943-023-01849-0","article-title":"Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics","volume":"22","author":"Gajbhiye","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2025.189318_bb0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.nxmate.2024.100128","article-title":"Role of nanoparticles in enhancing chemotherapy efficacy for cancer treatment","volume":"2","author":"Ghazal","year":"2024","journal-title":"Next Materials"},{"key":"10.1016\/j.bbcan.2025.189318_bb0635","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1039\/D0CS01127D","article-title":"Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine","volume":"50","author":"Sousa de Almeida","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.bbcan.2025.189318_bb0640","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jconrel.2019.06.025","article-title":"Tailoring the lipid composition of nanoparticles modulates their cellular uptake and affects the viability of triple negative breast cancer cells","volume":"307","author":"Abumanhal-Masarweh","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbcan.2025.189318_bb0645","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00000658-199508000-00009","article-title":"Transforming growth factor-beta receptors and mannose 6-phosphate\/insulin-like growth factor-II receptor expression in human hepatocellular carcinoma","volume":"222","author":"Sue","year":"1995","journal-title":"Ann. Surg."},{"key":"10.1016\/j.bbcan.2025.189318_bb0650","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.addr.2020.06.017","article-title":"Lipid-based nanoparticle technologies for liver targeting","volume":"154\u2013155","author":"B\u00f6ttger","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbcan.2025.189318_bb0655","article-title":"Recent advances of novel targeted drug delivery systems based on natural medicine monomers against hepatocellular carcinoma","volume":"10","author":"Ji","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.bbcan.2025.189318_bb0660","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/hep.24477","article-title":"Hepatocyte cytotoxicity is facilitated by asialoglycoprotein receptor","volume":"54","author":"Guy","year":"2011","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.bbcan.2025.189318_bb0665","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/ddr.21758","article-title":"Surface receptor-mediated targeted drug delivery systems for enhanced cancer treatment: a state-of-the-art review","volume":"82","author":"Kunjiappan","year":"2021","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bbcan.2025.189318_bb0670","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1080\/19420862.2017.1373924","article-title":"Capacity limits of asialoglycoprotein receptor-mediated liver targeting","volume":"9","author":"Bon","year":"2017","journal-title":"mAbs"},{"key":"10.1016\/j.bbcan.2025.189318_bb0675","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0005-2736(97)00036-9","article-title":"Biodistribution of liposomes containing synthetic galactose-terminated diacylglyceryl-poly(ethyleneglycol)s","volume":"1326","author":"Shimada","year":"1997","journal-title":"Biochimica et Biophysica Acta (BBA) - Biomembranes"},{"key":"10.1016\/j.bbcan.2025.189318_bb0680","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3390\/nano6080141","article-title":"Galactosylated liposomes for targeted co-delivery of doxorubicin\/vimentin siRNA to hepatocellular carcinoma","volume":"6","author":"Oh","year":"2016","journal-title":"Nanomaterials"},{"key":"10.1016\/j.bbcan.2025.189318_bb0685","doi-asserted-by":"crossref","first-page":"37577","DOI":"10.1074\/jbc.M101786200","article-title":"Determination of the upper size limit for uptake and processing of ligands by the Asialoglycoprotein receptor on Hepatocytesin vitro and in vivo*","volume":"276","author":"Rensen","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2025.189318_bb0690","first-page":"1449","article-title":"Helper lipid structure influences protein adsorption and delivery of lipid nanoparticles to spleen and liver, biomaterials","volume":"9","author":"Zhang","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2025.189318_bb0695","doi-asserted-by":"crossref","first-page":"E10871","DOI":"10.1073\/pnas.1713390114","article-title":"Effect of removing Kupffer cells on nanoparticle tumor delivery","volume":"114","author":"Tavares","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2025.189318_bb0700","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202211420","article-title":"Optimizing lipid nanoparticles for delivery in primates","volume":"35","author":"Lam","year":"2023","journal-title":"Adv. Mater. (Deerfield Beach, Fla.)"},{"key":"10.1016\/j.bbcan.2025.189318_bb0705","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jconrel.2024.05.006","article-title":"The impact of, and expectations for, lipid nanoparticle technology: from cellular targeting to organelle targeting","volume":"370","author":"Sato","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbcan.2025.189318_bb0710","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.omtm.2023.06.005","article-title":"Lipid nanoparticle mRNA systems containing high levels of sphingomyelin engender higher protein expression in hepatic and extra-hepatic tissues, molecular therapy","volume":"30","author":"Chander","year":"2023","journal-title":"Meth. Clin. Develop."},{"key":"10.1016\/j.bbcan.2025.189318_bb0715","first-page":"e2404684","article-title":"Discovery of Ketal-Ester ionizable lipid nanoparticle with reduced hepatotoxicity, enhanced spleen tropism for mRNA vaccine delivery","volume":"vol. 11","author":"Lv","year":"2024","journal-title":"Adv. Sci. (Weinheim, Baden-Wurttemberg, Germany)"},{"key":"10.1016\/j.bbcan.2025.189318_bb0720","doi-asserted-by":"crossref","first-page":"17128","DOI":"10.1021\/acs.analchem.4c02399","article-title":"A cell-free kinetic analysis of Ionizable lipid hydrolysis","volume":"96","author":"Couture-Sen\u00e9cal","year":"2024","journal-title":"Anal. Chem."},{"key":"10.1016\/j.bbcan.2025.189318_bb0725","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1021\/mp800049w","article-title":"Pharmacokinetics and biodistribution of nanoparticles","volume":"5","author":"Li","year":"2008","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bbcan.2025.189318_bb0730","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.addr.2007.11.006","article-title":"Targeted delivery of nanoparticles for the treatment of lung diseases","volume":"60","author":"Azarmi","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbcan.2025.189318_bb0735","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2353\/ajpath.2010.090136","article-title":"The role of liver sinusoidal cells in hepatocyte-directed gene transfer","volume":"176","author":"Jacobs","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbcan.2025.189318_bb0740","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0014-5793(99)00364-6","article-title":"On the mechanism of hepatic transendothelial passage of large liposomes","volume":"448","author":"Romero","year":"1999","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bbcan.2025.189318_bb0745","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189318_bb0750","series-title":"Tumour vasculature targeted anti-cancer therapy, Tumour vasculature targeted anti-cancer therapy","first-page":"14","volume":"4","author":"Debabrata Ghosh","year":"2020"},{"key":"10.1016\/j.bbcan.2025.189318_bb0755","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","article-title":"Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review","volume":"65","author":"Maeda","year":"2000","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbcan.2025.189318_bb0760","first-page":"3752","article-title":"Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size","volume":"55","author":"Yuan","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189318_bb0765","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/382184","article-title":"Efficient hepatic delivery of drugs: novel strategies and their significance","volume":"2013","author":"Mishra","year":"2013","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.bbcan.2025.189318_bb0770","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jconrel.2015.02.022","article-title":"Asialoglycoprotein receptor mediated hepatocyte targeting - strategies and applications","volume":"203","author":"D'Souza","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbcan.2025.189318_bb0775","article-title":"Recent advances in understanding the protein Corona of nanoparticles and in the formulation of \u201cstealthy\u201d","volume":"8","author":"Rampado","year":"2020","journal-title":"Nanomaterials"},{"key":"10.1016\/j.bbcan.2025.189318_bb0780","article-title":"Protein adsorption: a feasible method for nanoparticle functionalization?","volume":"12","author":"Cagliani","year":"2019","journal-title":"Materials (Basel, Switzerland)"},{"key":"10.1016\/j.bbcan.2025.189318_bb0785","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3109\/02652049809006836","article-title":"Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study","volume":"15","author":"Alyautdin","year":"1998","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.bbcan.2025.189318_bb0790","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/10611860500071292","article-title":"Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns","volume":"13","author":"G\u00f6ppert","year":"2005","journal-title":"J. Drug Target."},{"key":"10.1016\/j.bbcan.2025.189318_bb0795","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijpharm.2005.10.010","article-title":"Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles","volume":"307","author":"Owens","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bbcan.2025.189318_bb0800","article-title":"Phospholipid-free small Unilamellar vesicles for drug targeting to cells in the liver","volume":"15","author":"Zhang","year":"2019","journal-title":"Small (Weinheim an der Bergstrasse, Germany)"},{"key":"10.1016\/j.bbcan.2025.189318_bb0805","first-page":"1357","article-title":"Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms, molecular therapy: the journal of the American society of","volume":"18","author":"Akinc","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.bbcan.2025.189318_bb0810","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nbt1396","article-title":"Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone","volume":"26","author":"Sato","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbcan.2025.189318_bb0815","series-title":"Vitamin a storage in hepatic stellate cells in the regenerating rat liver: with special reference to zonal heterogeneity, the anatomical record. Part A, Discoveries in molecular, cellular, and evolutionary biology","first-page":"899","volume":"286","author":"Higashi","year":"2005"},{"key":"10.1016\/j.bbcan.2025.189318_bb0820","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2147\/IJN.S68861","article-title":"Liposomes as nanomedical devices","volume":"10","author":"Bozzuto","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.bbcan.2025.189318_bb0825","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e09394","article-title":"Liposomes: structure, composition, types, and clinical applications","volume":"8","author":"Nsairat","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.bbcan.2025.189318_bb0830","series-title":"Recent Advances in Doxorubicin Formulation to Enhance Pharmacokinetics and Tumor Targeting","first-page":"802","volume":"16","author":"Lee","year":"2023"},{"key":"10.1016\/j.bbcan.2025.189318_bb0835","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae--the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbcan.2025.189318_bb0840","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.omtn.2017.03.010","article-title":"MiR-375 and doxorubicin co-delivered by liposomes for combination therapy of hepatocellular carcinoma","volume":"7","author":"Fan","year":"2017","journal-title":"Molecular Therapy - Nucleic Acids"},{"key":"10.1016\/j.bbcan.2025.189318_bb0845","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","article-title":"Doxorubicin pathways: pharmacodynamics and adverse effects","volume":"21","author":"Thorn","year":"2011","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.bbcan.2025.189318_bb0850","series-title":"Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems","first-page":"157","volume":"65","author":"Tacar","year":"2013"},{"key":"10.1016\/j.bbcan.2025.189318_bb0855","series-title":"xPharm: The Comprehensive Pharmacology Reference","first-page":"1","article-title":"Doxorubicin","author":"Agrawal","year":"2007"},{"key":"10.1016\/j.bbcan.2025.189318_bb0860","doi-asserted-by":"crossref","first-page":"17029","DOI":"10.1039\/D0NR01908A","article-title":"A novel targeted delivery system for drug-resistant hepatocellular carcinoma therapy","volume":"12","author":"Xiao","year":"2020","journal-title":"Nanoscale"},{"key":"10.1016\/j.bbcan.2025.189318_bb0865","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/psc.2599","article-title":"Screening and identification of a specific peptide binding to hepatocellular carcinoma cells from a phage display peptide library","volume":"20","author":"Guo","year":"2014","journal-title":"J. Peptide Sci."},{"key":"10.1016\/j.bbcan.2025.189318_bb0870","doi-asserted-by":"crossref","first-page":"22003","DOI":"10.1021\/acsomega.2c02584","article-title":"Research on the construction of bispecific-targeted sustained-release drug-delivery microspheres and their function in treatment of hepatocellular carcinoma","volume":"7","author":"Huang","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.bbcan.2025.189318_bb0875","series-title":"Lenvatinib resistance mechanism and potential ways to conquer","volume":"14","author":"Bo","year":"2023"},{"key":"10.1016\/j.bbcan.2025.189318_bb0880","series-title":"Comprehensive Heterocyclic Chemistry IV","first-page":"217","article-title":"7.06 - pyridines and their benzo derivatives: Applications","author":"McAteer","year":"2022"},{"key":"10.1016\/j.bbcan.2025.189318_bb0885","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.3390\/pharmaceutics16091128","article-title":"HER-2 receptor and \u03b1v\u03b23 integrin dual-ligand surface-functionalized liposome for metastatic breast Cancer therapy","volume":"16","author":"Arya","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bbcan.2025.189318_bb0890","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3390\/pharmaceutics14020458","article-title":"Increased targeting area in tumors by dual-ligand modification of liposomes with RGD and TAT peptides","volume":"14","author":"Amin","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bbcan.2025.189318_bb0895","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1021\/acs.molpharmaceut.2c00842","article-title":"Dual-ligand-functionalized liposomes based on Glycyrrhetinic acid and cRGD for hepatocellular carcinoma targeting and therapy","volume":"20","author":"Qiu","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bbcan.2025.189318_bb0900","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc2748","article-title":"Integrins in cancer: biological implications and therapeutic opportunities","volume":"10","author":"Desgrosellier","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2025.189318_bb0905","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41568-018-0038-z","article-title":"Every step of the way: integrins in cancer progression and metastasis","volume":"18","author":"Hamidi","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2025.189318_bb0910","first-page":"27","article-title":"Recent advances in glycyrrhetinic acid-functionalized biomaterials for liver cancer-targeting therapy","author":"Speciale","year":"2022","journal-title":"Molecules (Basel, Switzerland)"},{"key":"10.1016\/j.bbcan.2025.189318_bb0915","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14030573","article-title":"Sequential drug delivery in targeted Cancer therapy","volume":"14","author":"Yu","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bbcan.2025.189318_bb0920","doi-asserted-by":"crossref","DOI":"10.3390\/cells13211819","article-title":"Celastrol-loaded hyaluronic acid\/Cancer cell membrane lipid nanoparticles for targeted hepatocellular carcinoma prevention","volume":"13","author":"He","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.bbcan.2025.189318_bb0925","first-page":"297","article-title":"Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential","volume":"1","author":"Immordino","year":"2006","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.bbcan.2025.189318_bb0930","article-title":"Liposomes for tumor targeted therapy: a review","volume":"24","author":"Wang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2025.189318_bb0935","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1038\/s41467-024-48838-5","article-title":"Rediscovery of mononuclear phagocyte system blockade for nanoparticle drug delivery","volume":"15","author":"Zelepukin","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2025.189318_bb0940","first-page":"418","article-title":"Smart nanoparticles for cancer therapy, signal transduction and targeted","volume":"8","author":"Sun","year":"2023","journal-title":"Therapy"},{"key":"10.1016\/j.bbcan.2025.189318_bb0945","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23084153","article-title":"Crossing the blood-brain barrier: advances in nanoparticle Technology for Drug Delivery in neuro-oncology","volume":"23","author":"Hersh","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2025.189318_bb0950","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12951-018-0392-8","article-title":"Nano based drug delivery systems: recent developments and future prospects","volume":"16","author":"Patra","year":"2018","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.bbcan.2025.189318_bb0955","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41392-017-0004-3","article-title":"Controlled drug delivery vehicles for cancer treatment and their performance","volume":"3","author":"Senapati","year":"2018","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2025.189318_bb0960","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3762\/bjoc.11.22","article-title":"Formulation development, stability and anticancer efficacy of core-shell cyclodextrin nanocapsules for oral chemotherapy with camptothecin","volume":"11","author":"\u00dcnal","year":"2015","journal-title":"Beilstein J. Org. Chem."},{"key":"10.1016\/j.bbcan.2025.189318_bb0965","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1158\/1535-7163.MCT-07-2359","article-title":"Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery","volume":"7","author":"Lo","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2025.189318_bb0970","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nmat2992","article-title":"The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers","volume":"10","author":"Ashley","year":"2011","journal-title":"Nat. Mater."},{"key":"10.1016\/j.bbcan.2025.189318_bb0975","first-page":"389","article-title":"Hepatocellular carcinoma-targeted nanoparticles for cancer therapy","volume":"52","author":"Wu","year":"2018","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bbcan.2025.189318_bb0980","first-page":"5045","article-title":"Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules","volume":"60","author":"Ngan","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189318_bb0985","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1124\/mol.60.1.225","article-title":"Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine","volume":"60","author":"Ngan","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbcan.2025.189318_bb0990","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2174\/138945012802009017","article-title":"Vinorelbine in cancer therapy","volume":"13","author":"Capasso","year":"2012","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.bbcan.2025.189318_bb0995","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jconrel.2021.01.021","article-title":"Ultra-small lipid nanoparticles encapsulating sorafenib and midkine-siRNA selectively-eradicate sorafenib-resistant hepatocellular carcinoma in vivo","volume":"331","author":"Younis","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbcan.2025.189318_bb1000","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2183\/pjab.86.410","article-title":"Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases","volume":"86","author":"Muramatsu","year":"2010","journal-title":"Proc. Japan Acad. Ser. B Phys. Biol. Sci."},{"key":"10.1016\/j.bbcan.2025.189318_bb1005","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2217\/hep.13.20","article-title":"Sorafenib for the treatment of hepatocellular carcinoma","volume":"1","author":"W\u00f6rns","year":"2014","journal-title":"Hepatic Oncol."},{"key":"10.1016\/j.bbcan.2025.189318_bb1010","doi-asserted-by":"crossref","first-page":"9283","DOI":"10.2147\/IJN.S277545","article-title":"Cationic solid lipid nanoparticles of resveratrol for hepatocellular carcinoma treatment: systematic optimization, in vitro characterization and preclinical investigation","volume":"15","author":"Rahman","year":"2020","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.bbcan.2025.189318_bb1015","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18122589","article-title":"The role of resveratrol in Cancer therapy","volume":"18","author":"Ko","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2025.189318_bb1020","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.canlet.2021.05.001","article-title":"Resveratrol for cancer therapy: challenges and future perspectives","volume":"515","author":"Ren","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2025.189318_bb1025","doi-asserted-by":"crossref","first-page":"6635","DOI":"10.4049\/jimmunol.173.11.6635","article-title":"IL-12 gene therapy is an effective therapeutic strategy for hepatocellular carcinoma in immunosuppressed mice","volume":"173","author":"Harada","year":"2004","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"key":"10.1016\/j.bbcan.2025.189318_bb1030","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s11010-016-2687-0","article-title":"Interleukin-12 inhibits the hepatocellular carcinoma growth by inducing macrophage polarization to the M1-like phenotype through downregulation of Stat-3","volume":"415","author":"Wang","year":"2016","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.bbcan.2025.189318_bb1035","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1084\/jem.188.1.133","article-title":"Interferon gamma-independent rejection of interleukin 12-transduced carcinoma cells requires CD4+ T cells and granulocyte\/macrophage colony-stimulating factor","volume":"188","author":"Zilocchi","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbcan.2025.189318_bb1040","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/jnci\/89.14.1049","article-title":"Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12","volume":"89","author":"Cavallo","year":"1997","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbcan.2025.189318_bb1045","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s40425-018-0431-x","article-title":"Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma","volume":"6","author":"Ian","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2025.189318_bb1050","series-title":"Single-Layer MoS2 Nanosheets with Amplified Photoacoustic Effect for Highly Sensitive Photoacoustic Imaging of Orthotopic Brain Tumors","first-page":"8715","volume":"26","author":"Chen","year":"2016"},{"key":"10.1016\/j.bbcan.2025.189318_bb1055","first-page":"472","article-title":"Nanomaterials for photoacoustic imaging in the second near-infrared window, biomaterials","volume":"7","author":"Huang","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2025.189318_bb1060","series-title":"Multifunctional Systems for Combined Delivery","first-page":"245","article-title":"Chapter 13 - therapeutic nanoparticles for targeted delivery of anticancer drugs","author":"Alasvand","year":"2017"},{"key":"10.1016\/j.bbcan.2025.189318_bb1065","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11080771","article-title":"The enhanced permeability and retention (EPR) effect: the significance of the concept and methods to enhance its application","volume":"11","author":"Wu","year":"2021","journal-title":"J. Personalized Med."},{"key":"10.1016\/j.bbcan.2025.189318_bb1070","series-title":"Nanocarriers for Cancer Diagnosis and Targeted Chemotherapy","first-page":"129","article-title":"Chapter 6 - Nanocarrier-based targeted pulmonary delivery: Novel approaches for effective lung cancer treatment","author":"Shah","year":"2019"},{"key":"10.1016\/j.bbcan.2025.189318_bb1075","series-title":"Biological Imaging Using Nanoparticles of Small Organic Molecules with Fluorescence Emission at Wavelengths Longer than 1000\u00a0nm","first-page":"13002","volume":"52","author":"Tao","year":"2013"},{"key":"10.1016\/j.bbcan.2025.189318_bb1080","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1039\/C9BM00528E","article-title":"Novel small molecular dye-loaded lipid nanoparticles with efficient near-infrared-II absorption for photoacoustic imaging and photothermal therapy of hepatocellular carcinoma","volume":"7","author":"Chen","year":"2019","journal-title":"Biomaterials Science"},{"key":"10.1016\/j.bbcan.2025.189318_bb1085","first-page":"1553","article-title":"Immunotherapy ofTumor RNA-Loaded Lipid Nanoparticles Against Hepatocellular Carcinoma","volume":"16","author":"Zhang","year":"2021","journal-title":"International journal ofnanomedicine"},{"key":"10.1016\/j.bbcan.2025.189318_bb1090","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/s13046-024-03167-9","article-title":"Co-delivery of camptothecin and MiR-145 by lipid nanoparticles for MRI-visible targeted therapy of hepatocellular carcinoma","volume":"43","author":"Rong","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189318_bb1095","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jcis.2021.06.151","article-title":"An MRI-guided targeting dual-responsive drug delivery system for liver cancer therapy","volume":"603","author":"Yao","year":"2021","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.bbcan.2025.189318_bb1100","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jconrel.2014.05.016","article-title":"Galactose-installed photo-crosslinked pH-sensitive degradable micelles for active targeting chemotherapy of hepatocellular carcinoma in mice","volume":"193","author":"Zou","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbcan.2025.189318_bb1105","first-page":"3952","article-title":"Hepatocyte-targeted delivery using oleanolic acid-loaded liposomes for enhanced hepatocellular carcinoma therapy, biomaterials","volume":"11","author":"Wei","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2025.189318_bb1110","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2165\/11539140-000000000-00000","article-title":"Safety of gadoterate meglumine (Gd-DOTA) as a contrast agent for magnetic resonance imaging: results of a post-marketing surveillance study in Japan","volume":"10","author":"Ishiguchi","year":"2010","journal-title":"Drugs R&D"},{"key":"10.1016\/j.bbcan.2025.189318_bb1115","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12951-023-02286-3","article-title":"Natural lipid nanoparticles extracted from Morus nigra L. leaves for targeted treatment of hepatocellular carcinoma via the oral route","volume":"22","author":"Gao","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.bbcan.2025.189318_bb1120","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241814041","article-title":"Lyophilization of nanoparticles, does it really work? Overview of the current status and challenges","volume":"24","author":"Gatto","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2025.189318_bb1125","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s43094-023-00551-8","article-title":"Process development and quality attributes for the freeze-drying process in pharmaceuticals, biopharmaceuticals and nanomedicine delivery: a state-of-the-art review","volume":"9","author":"Pardeshi","year":"2023","journal-title":"Fut. J. Pharmaceut. Sci."},{"key":"10.1016\/j.bbcan.2025.189318_bb1130","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines12101148","article-title":"Recent advances in lipid nanoparticles and their safety concerns for mRNA delivery","volume":"12","author":"Wang","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.bbcan.2025.189318_bb1135","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/s12276-023-01086-x","article-title":"Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics","volume":"55","author":"Lee","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bbcan.2025.189318_bb1140","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","article-title":"Innate immune mechanisms of mRNA vaccines","volume":"55","author":"Verbeke","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.bbcan.2025.189318_bb1145","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.addr.2021.03.004","article-title":"Oral lipid nanomedicines: current status and future perspectives in cancer treatment","volume":"173","author":"El Moukhtari","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbcan.2025.189318_bb1150","doi-asserted-by":"crossref","DOI":"10.1016\/j.onano.2022.100064","article-title":"Nanostructured lipid carriers and their potential applications for versatile drug delivery via oral administration","volume":"8","author":"Nguyen","year":"2022","journal-title":"OpenNano"},{"key":"10.1016\/j.bbcan.2025.189318_bb1155","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1111\/jocd.12891","article-title":"Nanostructured lipid carriers incorporating prickly pear seed oil for the encapsulation of vitamin A","volume":"18","author":"AlZahabi","year":"2019","journal-title":"Journal of cosmetic dermatology"},{"key":"10.1016\/j.bbcan.2025.189318_bb1160","series-title":"Lipid Nanoparticles: Production","author":"Shah","year":"2015"},{"key":"10.1016\/j.bbcan.2025.189318_bb1165","article-title":"Exploring the therapeutic potential of nanostructured lipid carrier approaches to tackling the inherent lacuna of chemotherapeutics and herbal drugs against breast cancer","volume":"63","author":"Sartaj","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.bbcan.2025.189318_bb1170","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12030288","article-title":"Nanostructured lipid carriers for delivery of chemotherapeutics: a review","volume":"12","author":"Haider","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bbcan.2025.189318_bb1175","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/1476-511X-11-159","article-title":"Nanostructured lipid carriers: a potential drug carrier for cancer chemotherapy","volume":"11","author":"Selvamuthukumar","year":"2012","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.bbcan.2025.189318_bb1180","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s43094-022-00414-8","article-title":"Nanostructured lipid carriers: a promising drug carrier for targeting brain tumours","volume":"8","author":"Garg","year":"2022","journal-title":"Fut. J. Pharmaceut. Sci."},{"key":"10.1016\/j.bbcan.2025.189318_bb1185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121712","article-title":"Pectin coated nanostructured lipid carriers for targeted piperine delivery to hepatocellular carcinoma","volume":"619","author":"Shehata","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bbcan.2025.189318_bb1190","doi-asserted-by":"crossref","first-page":"3851604","DOI":"10.1155\/2022\/3851604","article-title":"Norcantharidin nanostructured lipid carrier (NCTD-NLC) suppresses the viability of human hepatocellular carcinoma HepG2 cells and accelerates the apoptosis","volume":"2022","author":"Yan","year":"2022","journal-title":"J Immunol Res"},{"key":"10.1016\/j.bbcan.2025.189318_bb1195","doi-asserted-by":"crossref","first-page":"150","DOI":"10.34172\/apb.2020.021","article-title":"Nanostructured lipid carriers: a groundbreaking approach for transdermal drug delivery","volume":"10","author":"Chauhan","year":"2020","journal-title":"Adv. Pharmaceut. Bull."},{"key":"10.1016\/j.bbcan.2025.189318_bb1200","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.biopha.2018.04.055","article-title":"Nanostructured lipid carriers for site-specific drug delivery","volume":"103","author":"Khosa","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbcan.2025.189318_bb1205","article-title":"Nanostructured lipid carriers as a drug delivery system: a comprehensive review with therapeutic applications","author":"Mall","year":"2024","journal-title":"Intelligent Pharmacy"},{"key":"10.1016\/j.bbcan.2025.189318_bb1210","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12944-024-02429-x","article-title":"Preclinical advance in nanoliposome-mediated photothermal therapy in liver cancer","volume":"24","author":"Tang","year":"2025","journal-title":"Lipids Health Dis."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25000605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25000605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:31:55Z","timestamp":1778214715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X25000605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":242,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0304419X25000605"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189318","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive insights of etiological drivers of hepatocellular carcinoma: Fostering targeted nano delivery to anti-cancer regimes","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189318","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"189318"}}